FDA 483 - SCI Pharmtech Inc. - June 06, 2025

An FDA inspection of SCI Pharmtech Inc., an API manufacturer in Taoyuan City, Taiwan, revealed a significant issue with batch production records. The firm's records failed to include representative labels for APIs or commercially produced intermediates, indicating a deficiency in documentation practices. This observation highlights a concern regarding the completeness and accuracy of manufacturing records.